Janssen Prods patents expiration
1. Edurant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7067522 | JANSSEN PRODS | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(4 years ago) | |
| US6838464 | JANSSEN PRODS | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(3 years ago) | |
| US8080551 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(1 year, 15 days ago) | |
| US7125879 | JANSSEN PRODS | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101629 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(1 year, 8 months ago) | |
| US7638522 | JANSSEN PRODS | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
Apr, 2023
(1 year, 12 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 26, 2018 |
| M(M-223) | Feb 01, 2021 |
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
Drugs and Companies using RILPIVIRINE HYDROCHLORIDE ingredient
NCE-1 date: 21 May, 2015
Market Authorisation Date: 20 May, 2011
Treatment: In combination with other antiretroviral agents for the treatment of hiv-1 infection in treatment-naive adult patients with hiv-1 rna less than or equal to 100,000 at the start of therapy
Dosage: TABLET;ORAL
EDURANT family patents
2. Olysio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7671032 | JANSSEN PRODS | HCV NS-3 serine protease inhibitors |
May, 2025
(1 year, 23 days from now) | |
| US8741926 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US8754106 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US9856265 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US9040562 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US8349869 | JANSSEN PRODS | Macrocylic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US8148399 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9353103 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| US9623022 | JANSSEN PRODS | Macrocyclic inhibitors of hepatitis C virus |
Jul, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-717) | Oct 05, 2018 |
| New Indication(I-697) | Nov 05, 2017 |
| New Dosing Schedule(D-151) | Oct 05, 2018 |
| M(M-179) | May 20, 2019 |
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2018 |
| M(M-171) | Feb 26, 2019 |
Drugs and Companies using SIMEPREVIR SODIUM ingredient
NCE-1 date: 22 November, 2017
Market Authorisation Date: 22 November, 2013
Treatment: Method of treating hepatitis c
Dosage: CAPSULE;ORAL
OLYSIO family patents
3. Prezcobix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43596 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
May, 2017
(6 years ago) | |
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5843946 | JANSSEN PRODS | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Dec, 2015
(8 years ago) | |
|
US5843946 (Pediatric) | JANSSEN PRODS | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Jun, 2016
(7 years ago) | |
| USRE42889 | JANSSEN PRODS | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct, 2016
(7 years ago) | |
| USRE43802 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct, 2016
(7 years ago) | |
|
USRE43802 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr, 2017
(7 years ago) | |
|
USRE42889 (Pediatric) | JANSSEN PRODS | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr, 2017
(7 years ago) | |
|
USRE43596 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Nov, 2017
(6 years ago) | |
| US9889115 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US7470506 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US8597876 | JANSSEN PRODS | Method of treating HIV infection |
Jun, 2019
(4 years ago) | |
|
US7470506 (Pediatric) | JANSSEN PRODS | Fitness assay and associated methods |
Dec, 2019
(4 years ago) | |
|
US8597876 (Pediatric) | JANSSEN PRODS | Method of treating HIV infection |
Dec, 2019
(4 years ago) | |
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(3 months from now) | |
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(3 years from now) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: Treatment of hiv-1 infection in adults with no darunavir resistance-associated substitutions; Treatment of hiv infection in adults and pediatric patients weighing at least 40kg using a composition con...
Dosage: TABLET;ORAL
PREZCOBIX family patents
4. Prezista patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6335460 | JANSSEN PRODS | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
Aug, 2012
(11 years ago) | |
| US6248775 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Aug, 2014
(9 years ago) | |
| USRE43596 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
May, 2017
(6 years ago) | |
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6335460 (Pediatric) | JANSSEN PRODS | α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors |
Feb, 2013
(11 years ago) | |
|
US6248775 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Feb, 2015
(9 years ago) | |
| US5843946 | JANSSEN PRODS | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Dec, 2015
(8 years ago) | |
|
US5843946 (Pediatric) | JANSSEN PRODS | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Jun, 2016
(7 years ago) | |
| US6703403 | JANSSEN PRODS | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| US6037157 | JANSSEN PRODS | Method for improving pharmacokinetics |
Jun, 2016
(7 years ago) | |
| USRE43802 | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct, 2016
(7 years ago) | |
| USRE42889 | JANSSEN PRODS | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Oct, 2016
(7 years ago) | |
|
US6037157 (Pediatric) | JANSSEN PRODS | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
US6703403 (Pediatric) | JANSSEN PRODS | Method for improving pharmacokinetics |
Dec, 2016
(7 years ago) | |
|
USRE42889 (Pediatric) | JANSSEN PRODS | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr, 2017
(7 years ago) | |
|
USRE43802 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Apr, 2017
(7 years ago) | |
|
USRE43596 (Pediatric) | JANSSEN PRODS | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Nov, 2017
(6 years ago) | |
| US7470506 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US9889115 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US8597876 | JANSSEN PRODS | Method of treating HIV infection |
Jun, 2019
(4 years ago) | |
|
US7470506 (Pediatric) | JANSSEN PRODS | Fitness assay and associated methods |
Dec, 2019
(4 years ago) | |
|
US8597876 (Pediatric) | JANSSEN PRODS | Method of treating HIV infection |
Dec, 2019
(4 years ago) | |
|
US9889115 (Pediatric) | JANSSEN PRODS | Fitness assay and associated methods |
Dec, 2019
(4 years ago) | |
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(3 months from now) | |
|
US7700645 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-119) | Dec 18, 2011 |
| New Strength(NS) | Dec 18, 2011 |
| New Indication(I-578) | Oct 21, 2011 |
| New Dosing Schedule(D-118) | Oct 21, 2011 |
| New Dosing Schedule(D-135) | Feb 01, 2016 |
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 13, 2014 |
| New Dosing Schedule(D-129) | Dec 13, 2013 |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 18 December, 2008
Treatment: Treatment of hiv infection in antiretroviral treatment-experienced adult patients; Treatment of human immunodeficiency virus (hiv) infection in adult patients, and treatment of human immunodeficiency ...
Dosage: TABLET;ORAL; SUSPENSION;ORAL
PREZISTA family patents
5. Symtuza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6703396 | JANSSEN PRODS | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| US7390791 | JANSSEN PRODS | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| US9296769 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US8754065 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9889115 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US7470506 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US8597876 | JANSSEN PRODS | Method of treating HIV infection |
Jun, 2019
(4 years ago) | |
| US6642245 | JANSSEN PRODS | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
| US7803788 | JANSSEN PRODS | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| US10786518 | JANSSEN PRODS | Compositions and methods of treating HIV |
Jul, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 i...
Dosage: TABLET;ORAL
SYMTUZA family patents
6. Yondelis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895557 | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jan, 2028
(3 years from now) | |
|
US8895557 (Pediatric) | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 23, 2020 |
| Orphan Drug Exclusivity(ODE) | Oct 23, 2022 |
| Orphan Drug Exclusivity(ODE-100) | Oct 23, 2022 |
| M(M-232) | Jun 29, 2021 |
| Pediatric Exclusivity(PED) | Apr 23, 2023 |
Drugs and Companies using TRABECTEDIN ingredient
NCE-1 date: 23 April, 2022
Market Authorisation Date: 23 October, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
YONDELIS family patents